Congress Materials

Medical Information
Ireland
 

In order to provide you with relevant and meaningful content we need to know more about you.

Please choose the category that best describes you.

This content is intended for U.S. Healthcare Professionals. Would you like to proceed?

I am a healthcare professionalYes, I am a healthcare professional
SelectI am a healthcare professionalYes, I am a healthcare professional
I am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal
SelectI am a Patient/Caregiver or
Member of the General PublicNo, go back to the patient portal

If you don't reside in Ireland, please click here

The medical information on this site is intended only for healthcare professionals in the Republic of Ireland. The products discussed herein may have different product labeling in other countries.

This information is not intended as medical advice. Responsibility for patient care resides with the healthcare professional on the basis of his or her professional license, experience and knowledge of the patient.

Congress Materials

The information on this page pertains to select congresses, congress materials, therapeutic and disease areas. It is not intended to serve as a comprehensive overview of all congresses, congress materials, therapeutic and disease areas.
Congress materials may include information for which the product is not approved and/or inconsistent with the product uses described in the Prescribing Information. Pfizer does not suggest or recommend the use of Pfizer Products in any manner other than as described in the Prescribing Information.
Oral Presentation
Buch MH, Mortezavi M, Giles J, Charles-Schoeman C, Karpouzas G, Jo H, Kwok K, Nagy E, Rivas JL, Yndestad A May 31, 2023 EULAR 2023 Rheumatoid Arthritis

Impact of cardiovascular comorbidities on efficacy of tofacitinib vs TNFi in rheumatoid arthritis

View Presentation
Oral Presentation
Eder L, Richette P, Coates L, Azevedo VF, Cappelleri JC, Hoang M, Moser J, Kinch C, Kessouri M May 31, 2023 EULAR 2023 Psoriatic Arthritis

Sex differences in perceptions of psoriatic arthritis disease impact, management and physician interactions: results from a global patient survey

View Presentation
Poster
Cohen SB, Schulze-Koops H, Pope J, Gold D, Cadatal MJ, Schroeder G, Diehl A, Nagy E, Duench S, Rubbert-Roth A June 1, 2023 EULAR 2023 Rheumatoid Arthritis

Clinical outcomes of patients with rheumatoid arthritis who discontinued tofacitinib or tumour necrosis factor inhibitors: results from ORAL Surveillance

View Presentation
Poster
Brunner H, Wasserman H, Saul M, Robinson D, Nagy E, Diehl A, Mortezavi M June 1, 2023 EULAR 2023 Juvenile Idiopathic Arthritis

Impact of tofacitinib treatment on height in juvenile idiopathic arthritis

View Presentation
Poster
Gottenberg J-E, Kessouri M, Rudant J, Assi N, Raguideau F, Kirchgesner J June 1, 2023 EULAR 2023 Rheumatoid Arthritis

Malignancies risk In Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a National Study: RELATION study

View Presentation
Poster
Burmester GR, Coates L, Cohen SB, Tanaka Y, Vranic I, Nagy E, Chen A-S, Lazariciu I, Kwok K, Fallon L, Kinch C June 2, 2023 EULAR 2023 Rheumatoid Arthritis, Psoriatic Arthritis

Post-marketing safety surveillance of tofacitinib over 9 years in patients with rheumatoid arthritis and psoriatic arthritis

View Presentation
Poster
Navarro-Compán V, Deodhar A, Bahiri R, Bushmakin AG, Cappelleri JC, Kinch C, Rammaoui J June 2, 2023 EULAR 2023 Ankylosing Spondylitis

Time to improvement of pain, morning stiffness and disease activity in patients with ankylosing spondylitis treated with tofacitinib

View Presentation
Poster
Gottenberg J-E, Kessouri M, Rudant J, Assi N, Grenier B, Kirchgesner J June 3, 2023 EULAR 2023 Rheumatoid Arthritis

Acute Cardiovascular Events risk In Rheumatoid Arthritis Patients Treated with Tofacitinib or TNF Inhibitors, a Nationwide Cohort Study: RELATION study

View Presentation
Poster
Gladman DD, Dougados M, Marzo-Ortega H, Cadatal MJ, Kinch C, Nash P June 3, 2023 EULAR 2023 Psoriatic Arthritis

Long-term safety and efficacy of tofacitinib in patients with psoriatic arthritis by prior biologic disease-modifying antirheumatic drug exposure

View Presentation